J D Sokolowski1, L S Seiden. 1. Department of Neurobiology, Pharmacology and Physiology, University of Chicago, 947E. 58th St., Chicago, IL 60637, USA.
Abstract
RATIONALE: Recent evidence indicates that specific serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) are not a clinically or experimentally homogeneous class of drugs. Because the differential- reinforcement-of-low-rates 72-second (DRL 72-s) operant schedule has been extensively used as a screen for antidepressant effects of drugs, different SSRIs were compared on the task to further examine their behavioral effects. OBJECTIVES: These experiments were designed with two main purposes in mind: first, to determine whether all three SSRIs tested would produce antidepressant-like effects on the DRL 72-s (as measured primarily by an increase in reinforcement rate) and, second, to identify differences between the drugs using peak-deviation analysis of inter-response times (IRTs). METHODS: Different groups of rats were injected with one of three SSRIs: fluoxetine, sertraline, or paroxetine. Following drug administration, rats were tested on the DRL 72-s operant schedule. RESULTS: All three SSRIs produced significant increases in reinforcement rate, but only sertraline and fluoxetine significantly decreased response rate. Additionally, paroxetine was observed to disrupt the pattern of responding as indicated by decreases in peak area (PkA). Sertraline and paroxetine, but not fluoxetine, produced increases in peak location (PkL). CONCLUSIONS: These results indicate that, although SSRIs are correctly identified as antidepressants by the DRL 72-s operant schedule, they may exert their effects in subtly different ways, as indicated by the differences observed to exist between the drugs. It appears unlikely that the behavioral effects of the SSRIs are attributable solely to 5-HT transporter binding. Instead, the differential behavioral effects may be the result of a combination of factors, including 5-HT transporter binding, 5-HT(1A) autoreceptor activation, and binding to other receptors.
RATIONALE: Recent evidence indicates that specific serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) are not a clinically or experimentally homogeneous class of drugs. Because the differential- reinforcement-of-low-rates 72-second (DRL 72-s) operant schedule has been extensively used as a screen for antidepressant effects of drugs, different SSRIs were compared on the task to further examine their behavioral effects. OBJECTIVES: These experiments were designed with two main purposes in mind: first, to determine whether all three SSRIs tested would produce antidepressant-like effects on the DRL 72-s (as measured primarily by an increase in reinforcement rate) and, second, to identify differences between the drugs using peak-deviation analysis of inter-response times (IRTs). METHODS: Different groups of rats were injected with one of three SSRIs: fluoxetine, sertraline, or paroxetine. Following drug administration, rats were tested on the DRL 72-s operant schedule. RESULTS: All three SSRIs produced significant increases in reinforcement rate, but only sertraline and fluoxetine significantly decreased response rate. Additionally, paroxetine was observed to disrupt the pattern of responding as indicated by decreases in peak area (PkA). Sertraline and paroxetine, but not fluoxetine, produced increases in peak location (PkL). CONCLUSIONS: These results indicate that, although SSRIs are correctly identified as antidepressants by the DRL 72-s operant schedule, they may exert their effects in subtly different ways, as indicated by the differences observed to exist between the drugs. It appears unlikely that the behavioral effects of the SSRIs are attributable solely to 5-HT transporter binding. Instead, the differential behavioral effects may be the result of a combination of factors, including 5-HT transporter binding, 5-HT(1A) autoreceptor activation, and binding to other receptors.
Authors: Noelle C Anastasio; Erin C Stoffel; Robert G Fox; Marcy J Bubar; Kenner C Rice; Frederick G Moeller; Kathryn A Cunningham Journal: Behav Pharmacol Date: 2011-06 Impact factor: 2.293
Authors: Ari P Kirshenbaum; Eric R Jackson; Seth J Brown; Jason R Fuchs; Betsie C Miltner; Adam H Doughty Journal: Behav Pharmacol Date: 2011-06 Impact factor: 2.293
Authors: Han-Ting Zhang; Lisa R Whisler; Ying Huang; Yang Xiang; James M O'Donnell Journal: Neuropsychopharmacology Date: 2008-10-15 Impact factor: 7.853
Authors: Hiske M van der Stelt; Laus M Broersen; Berend Olivier; Herman G M Westenberg Journal: Psychopharmacology (Berl) Date: 2003-11-25 Impact factor: 4.530